Table 1.
Laboratory findings at initial visit and after pioglitazone treatment
| Initial visit | After pioglitazone treatment | |||
|---|---|---|---|---|
| 3 months | 6 months | 18 months | ||
| Bodyweight (kg) | 40.8 | 41.4 | ||
| BMI (kg/m2) | 15.0 | 15.2 | ||
| HbA1c (%) | 8.6 | 8.6 | 9.6 | 8.8 |
| FBS (mg/dL) | 197 | 190 | 205 | |
| IRI (μU/L) | 25.6 | 41.2 | ||
| CPR (ng/mL) | 3.64 | 4.25 | ||
| Total cholesterol (mg/dL) | 206 | 203 | ||
| HDL cholesterol (mg/dL) | 26 | 27 | 28 | 25 |
| LDL cholesterol (mg/dL) | 169 | 164 | 168 | 169 |
| Triglyceride (mg/dL) | 130 | 246 | 196 | 132 |
| AST (U/L) | 61 | 64 | 89 | 44 |
| ALT (U/L) | 132 | 111 | 125 | 101 |
| γGTP (U/L) | 60 | 47 | 60 | 51 |
| Albumin (g/dL) | 4.7 | 4.3 | 4.4 | 4.6 |
| Total bilirubin (mg/dL) | 0.9 | 0.7 | ||
| Platelet (104/μL) | 15.5 | 14.1 | 14.8 | 16.7 |
| Serum creatinine (mg/dL) | 0.12 | 0.10 | 0.14 | 0.17 |
| Fasting leptin (ng/mL) | 2.8 | 3.2 | ||
| Fasting adiponectin (μg/mL) | 2.5 | 2.9 | ||
| Visceral fat area (cm2) | 44.7 | 79.2 | ||
| Subcutaneous fat area (cm2) | 6.4 | 12.0 | ||
| HBsAg | (–) | |||
| HCV antibody | (–) | |||
| Anti‐mitochondrial antibody | <1.5 | |||
| Type IV collagen (ng/mL) | 6.5 | 6.1 | ||
| Hyaluronic acid (ng/mL) | 21 | 11 | ||
| Fibroscan (kPa) | 13.2 | 11.4 | ||
Reference values for type IV collagen, hyaluronic acid, and fibroscan are <6 ng/mL, <50 ng/mL and <7 kPa, respectively. γGTP, gamma‐glutamyltransferase; ALT, alanine transaminase; AST, aspartate transaminase; BMI, body mass index; CPR, C‐peptide reactivity; FBS, fasting blood glucose; HbA1c, glycated hemoglobin; HBsAg, hepatitis B virus surface antigen; HCV, hepatitis C virus; HDL, high‐density lipoprotein; IRI, immunoreactive insulin; LDL, low‐density lipoprotein.